Moderna’s Early Good News

Moderna protocol files for COVID-19 vaccinations. Research Centers of America, Hollywood, Florida, August 13, 2020. Image: Chandan Khanna/AFP/Getty
Image credit
Moderna protocol files for COVID-19 vaccinations. Research Centers of America, Hollywood, Florida, August 13, 2020. Image: Chandan Khanna/AFP/Getty

More good vaccine news broke this morning as biotech company Moderna announced preliminary findings that its vaccine had 94.5% efficacy against SAR-CoV-2.

While data and a peer-reviewed article are yet to be published, the announcement stokes much-needed optimism as COVID-19 is again scorching the US and Europe, The Washington Post reports.

The Moderna results follow last Monday’s announcement that Pfizer’s vaccine had 90% efficacy.

Trial Details: Of the 30,000 participants in the Moderna trial, 95 people have developed COVID-19 so far—90 of whom had received a placebo and 5 the vaccine. None of the 11 severe cases had been given the vaccine.

Timeline: Health care workers and others at high-risk could receive the vaccine by the end of the year.

Advantage: Unlike the Pfizer vaccine, which so far must be kept frozen at -70 degrees C, the Moderna vaccine (co-developed with NIAID) can be kept at refrigerator temperatures for a month. 

Comments +

0 comments

Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top